<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>

<channel>
	<title>Hayes &#187; Health Technology Assessment &#038; Consulting</title>
	<atom:link href="http://www.hayesinc.com/hayes/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.hayesinc.com/hayes</link>
	<description>Transforming Healthcare with Evidence</description>
	<pubDate>Wed, 10 Mar 2010 05:49:33 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.5.1</generator>
	<language>en</language>
			<item>
		<title>Name Change Approved for Kapidex™</title>
		<link>http://www.hayesinc.com/hayes/2010/03/09/name-change-approved-for-kapidex%e2%84%a2/</link>
		<comments>http://www.hayesinc.com/hayes/2010/03/09/name-change-approved-for-kapidex%e2%84%a2/#comments</comments>
		<pubDate>Tue, 09 Mar 2010 16:00:00 +0000</pubDate>
		<dc:creator>it</dc:creator>
		
		<category><![CDATA[News Service]]></category>

		<guid isPermaLink="false">http://www.hayesinc.com/hayes/2010/03/09/name-change-approved-for-kapidex%e2%84%a2/</guid>
		<description><![CDATA[

			
				The Food and Drug Administration (FDA) has approved a name change for the heartburn drug Kapidex (dexlansoprazole) to avoid confusion with two other medications—Casodex and Kadian. Effective in late April 2010, Takeda Pharmaceuticals North America Inc. will market Kapidex under the new name Dexilant™.
			

Since Kapidex was approved in January 2009, there have been reports of [...]]]></description>
		<wfw:commentRss>http://www.hayesinc.com/hayes/2010/03/09/name-change-approved-for-kapidex%e2%84%a2/feed/</wfw:commentRss>
		</item>
		<item>
		<title>New WHI Analysis Finds No Cardioprotective Effect In Postmenopausal Women During First 6 Years of Combination Hormone Therapy</title>
		<link>http://www.hayesinc.com/hayes/2010/03/08/new-whi-analysis-finds-no-cardioprotective-effect-in-postmenopausal-women-during-first-6-years-of-combination-hormone-therapy/</link>
		<comments>http://www.hayesinc.com/hayes/2010/03/08/new-whi-analysis-finds-no-cardioprotective-effect-in-postmenopausal-women-during-first-6-years-of-combination-hormone-therapy/#comments</comments>
		<pubDate>Mon, 08 Mar 2010 16:00:00 +0000</pubDate>
		<dc:creator>it</dc:creator>
		
		<category><![CDATA[News Service]]></category>

		<guid isPermaLink="false">http://www.hayesinc.com/hayes/2010/03/08/new-whi-analysis-finds-no-cardioprotective-effect-in-postmenopausal-women-during-first-6-years-of-combination-hormone-therapy/</guid>
		<description><![CDATA[

			
				A retrospective analysis of data from the Women&#8217;s Health Initiative (WHI) published in the Annals of Internal Medicine suggests that combination hormone therapy (HT) increases risk for coronary heart disease (CHD) in healthy postmenopausal women during the first 2 years of use and offers no cardioprotection during the first 8 years of use. The increased [...]]]></description>
		<wfw:commentRss>http://www.hayesinc.com/hayes/2010/03/08/new-whi-analysis-finds-no-cardioprotective-effect-in-postmenopausal-women-during-first-6-years-of-combination-hormone-therapy/feed/</wfw:commentRss>
		</item>
		<item>
		<title>FDA Announces Class I Recall of Home Dialysis Systems</title>
		<link>http://www.hayesinc.com/hayes/2010/03/05/fda-announces-class-i-recall-of-home-dialysis-systems/</link>
		<comments>http://www.hayesinc.com/hayes/2010/03/05/fda-announces-class-i-recall-of-home-dialysis-systems/#comments</comments>
		<pubDate>Fri, 05 Mar 2010 16:00:00 +0000</pubDate>
		<dc:creator>it</dc:creator>
		
		<category><![CDATA[News Service]]></category>

		<guid isPermaLink="false">http://www.hayesinc.com/hayes/2010/03/05/fda-announces-class-i-recall-of-home-dialysis-systems/</guid>
		<description><![CDATA[

			
				The Food and Drug Administration (FDA) and Baxter Healthcare, the manufacturer of the HomeChoice and HomeChoice PRO dialysis systems, have notified patients of a Class I device recall after a number of reported injuries and one death. Recalls receive Class I status when there is reasonable probability that a device or drug will cause serious [...]]]></description>
		<wfw:commentRss>http://www.hayesinc.com/hayes/2010/03/05/fda-announces-class-i-recall-of-home-dialysis-systems/feed/</wfw:commentRss>
		</item>
		<item>
		<title>American Cancer Society Publishes New Guidelines for Prostate Cancer Screening</title>
		<link>http://www.hayesinc.com/hayes/2010/03/04/american-cancer-society-publishes-new-guidelines-for-prostate-cancer-screening/</link>
		<comments>http://www.hayesinc.com/hayes/2010/03/04/american-cancer-society-publishes-new-guidelines-for-prostate-cancer-screening/#comments</comments>
		<pubDate>Thu, 04 Mar 2010 16:00:00 +0000</pubDate>
		<dc:creator>it</dc:creator>
		
		<category><![CDATA[News Service]]></category>

		<guid isPermaLink="false">http://www.hayesinc.com/hayes/2010/03/04/american-cancer-society-publishes-new-guidelines-for-prostate-cancer-screening/</guid>
		<description><![CDATA[

			
				According to newly revised guidelines from the American Cancer Society (ACS), men should discuss the benefits and risks of prostate cancer screening with their doctors. While this is not a radical change from the previous recommendations, the new guidelines offer clearer guidance on what should be discussed. The revised recommendations, last updated in 2006, are [...]]]></description>
		<wfw:commentRss>http://www.hayesinc.com/hayes/2010/03/04/american-cancer-society-publishes-new-guidelines-for-prostate-cancer-screening/feed/</wfw:commentRss>
		</item>
		<item>
		<title>FDA Approves Prevnar 13 for Infants and Young Children</title>
		<link>http://www.hayesinc.com/hayes/2010/03/03/fda-approves-prevnar-13-for-infants-and-young-children/</link>
		<comments>http://www.hayesinc.com/hayes/2010/03/03/fda-approves-prevnar-13-for-infants-and-young-children/#comments</comments>
		<pubDate>Wed, 03 Mar 2010 16:00:00 +0000</pubDate>
		<dc:creator>it</dc:creator>
		
		<category><![CDATA[News Service]]></category>

		<guid isPermaLink="false">http://www.hayesinc.com/hayes/2010/03/03/fda-approves-prevnar-13-for-infants-and-young-children/</guid>
		<description><![CDATA[

			
				The Food and Drug Administration (FDA) has approved Prevnar 13™, a pneumococcal 13-valent conjugate vaccine, for infants and young children ages 6 weeks through 5 years. 
			

Prevnar 13 is the successor to Prevnar®, the pneumococcal 7-valent conjugate vaccine licensed by the FDA in 2000 to prevent invasive pneumococcal disease (IPD) and otitis media. The new [...]]]></description>
		<wfw:commentRss>http://www.hayesinc.com/hayes/2010/03/03/fda-approves-prevnar-13-for-infants-and-young-children/feed/</wfw:commentRss>
		</item>
		<item>
		<title>HHS Expands Opportunities for Consumers to Record Personalized Health Records</title>
		<link>http://www.hayesinc.com/hayes/2010/03/02/hhs-expands-opportunities-for-consumers-to-record-personalized-health-records/</link>
		<comments>http://www.hayesinc.com/hayes/2010/03/02/hhs-expands-opportunities-for-consumers-to-record-personalized-health-records/#comments</comments>
		<pubDate>Tue, 02 Mar 2010 16:00:00 +0000</pubDate>
		<dc:creator>it</dc:creator>
		
		<category><![CDATA[News Service]]></category>

		<guid isPermaLink="false">http://www.hayesinc.com/hayes/2010/03/02/hhs-expands-opportunities-for-consumers-to-record-personalized-health-records/</guid>
		<description><![CDATA[

			
				The office of the U.S. Surgeon General has announced a collaboration with Microsoft® HealthVault™ that will provide new features and expand access to My Family Health Portrait, a free Internet-based resource.
			


			
				
			My Family Health Portrait, a collaborative initiative supported by agencies of the Department of Health and Human Services (HHS), allows users to assemble their family [...]]]></description>
		<wfw:commentRss>http://www.hayesinc.com/hayes/2010/03/02/hhs-expands-opportunities-for-consumers-to-record-personalized-health-records/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Paroxetine May Increase Mortality Risk in Women Who Take Tamoxifen</title>
		<link>http://www.hayesinc.com/hayes/2010/03/01/paroxetine-may-increase-mortality-risk-in-women-who-take-tamoxifen/</link>
		<comments>http://www.hayesinc.com/hayes/2010/03/01/paroxetine-may-increase-mortality-risk-in-women-who-take-tamoxifen/#comments</comments>
		<pubDate>Mon, 01 Mar 2010 16:00:00 +0000</pubDate>
		<dc:creator>it</dc:creator>
		
		<category><![CDATA[News Service]]></category>

		<guid isPermaLink="false">http://www.hayesinc.com/hayes/2010/03/01/paroxetine-may-increase-mortality-risk-in-women-who-take-tamoxifen/</guid>
		<description><![CDATA[

			
				A study published in the British Journal of Medicine suggests that the antidepressant paroxetine (Paxil ™; GlaxoSmithKline) may significantly increase the risk of breast cancer mortality in women who also take tamoxifen. The same magnitude of risk was not noted with five similar antidepressants.  
			

It is estimated that up to 25% of women with [...]]]></description>
		<wfw:commentRss>http://www.hayesinc.com/hayes/2010/03/01/paroxetine-may-increase-mortality-risk-in-women-who-take-tamoxifen/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Health Plan Alliance ~ Spring Leadership Conference</title>
		<link>http://www.hayesinc.com/hayes/2010/02/25/health-plan-alliance-spring-leadership-conference/</link>
		<comments>http://www.hayesinc.com/hayes/2010/02/25/health-plan-alliance-spring-leadership-conference/#comments</comments>
		<pubDate>Thu, 25 Feb 2010 19:11:41 +0000</pubDate>
		<dc:creator>kim</dc:creator>
		
		<category><![CDATA[Upcoming Events]]></category>

		<category><![CDATA[What's New]]></category>

		<guid isPermaLink="false">http://www.hayesinc.com/hayes/?p=939</guid>
		<description><![CDATA[April 7-8, 2010
The Hilton Southlake
1400 Plaza Place, Southlake, TX 76902
Dr. Wini Hayes has been selected to make a presentation at the conference entitled,  “Creating Alignment between Plan and Provider with Technology Assessment and Review”. This presentation is scheduled during the session on Thursday, April 8th, from 11:00am – 12:00pm.
Presenter:

]]></description>
		<wfw:commentRss>http://www.hayesinc.com/hayes/2010/02/25/health-plan-alliance-spring-leadership-conference/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Obese Adolescents May Require Longer Needles for HBV Vaccination</title>
		<link>http://www.hayesinc.com/hayes/2010/02/25/obese-adolescents-may-require-longer-needles-for-hbv-vaccination/</link>
		<comments>http://www.hayesinc.com/hayes/2010/02/25/obese-adolescents-may-require-longer-needles-for-hbv-vaccination/#comments</comments>
		<pubDate>Thu, 25 Feb 2010 16:00:00 +0000</pubDate>
		<dc:creator>it</dc:creator>
		
		<category><![CDATA[News Service]]></category>

		<guid isPermaLink="false">http://www.hayesinc.com/hayes/2010/02/25/obese-adolescents-may-require-longer-needles-for-hbv-vaccination/</guid>
		<description><![CDATA[

			
				A study published in Pediatrics suggests that, when compared with standard length needles (1.0-inch), a longer (1.5-inch) needle yielded better results in obese adolescents after immunization with hepatitis B vaccine (HBV). Although all the participants in the study had enough antibodies to be considered protected against hepatitis B, the response was markedly less robust when [...]]]></description>
		<wfw:commentRss>http://www.hayesinc.com/hayes/2010/02/25/obese-adolescents-may-require-longer-needles-for-hbv-vaccination/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Public Comment Requested on Revised Definition of Human Embryonic Stem Cells</title>
		<link>http://www.hayesinc.com/hayes/2010/02/24/public-comment-requested-on-revised-definition-of-human-embryonic-stem-cells/</link>
		<comments>http://www.hayesinc.com/hayes/2010/02/24/public-comment-requested-on-revised-definition-of-human-embryonic-stem-cells/#comments</comments>
		<pubDate>Wed, 24 Feb 2010 16:00:00 +0000</pubDate>
		<dc:creator>it</dc:creator>
		
		<category><![CDATA[News Service]]></category>

		<guid isPermaLink="false">http://www.hayesinc.com/hayes/2010/02/24/public-comment-requested-on-revised-definition-of-human-embryonic-stem-cells/</guid>
		<description><![CDATA[

			
				The National Institutes of Health (NIH) is requesting public comment on a revision to the definition of human embryonic stem cells (hESCs) in the NIH “Guidelines for Human Stem Cell Research.”  
			


			
				
			The guidelines were initially implemented on July 7, 2009, to outline policies and procedures under which the NIH will fund stem cell research [...]]]></description>
		<wfw:commentRss>http://www.hayesinc.com/hayes/2010/02/24/public-comment-requested-on-revised-definition-of-human-embryonic-stem-cells/feed/</wfw:commentRss>
		</item>
	</channel>
</rss>
